Imagine a lifeline for nearly 500,000 Americans being controlled by just two companies. That's the reality of the dialysis industry today, where a duopoly allegedly prioritizes profits over patient care. Now, a leading U.S. senator is demanding answers. Senator Richard Blumenthal, a Connecticut Democrat, is urging federal regulators to reveal the findings of an investigation into this controversial sector. But here's where it gets controversial: Blumenthal suggests the government has failed to wield its antitrust powers effectively against these dominant players, Fresenius and DaVita, who together control a staggering 75% of U.S. dialysis clinics.
In an interview with CBS News, Blumenthal expressed concern over the "hallmarks of unlawful abuse of market power." He argues that the Federal Trade Commission (FTC), tasked with policing anti-competitive behavior, has yet to make its findings public. Blumenthal has called on the FTC to take "robust enforcement action" to protect patients, including 40,000 veterans, from potential misconduct by these companies.
Dialysis is a critical, life-sustaining treatment for those awaiting kidney transplants, yet critics claim the industry has become more about profit margins than patient well-being. Tom Mueller, author of How to Make a Killing: Blood, Death and Dollars in American Medicine, spent five years studying the industry and describes it as "emergency room care done in the mall," where patients often lack personalized treatment.
Duke University economist Ryan McDevitt highlights the alarming concentration of power in this sector, calling it "the most concentrated health care sector across the entire U.S." A CBS News review of federal data found that one-third of dialysis clinics failed to meet federal standards this year, with an average score of just 60 out of 100. Despite this, both Fresenius and DaVita claim their data reflects "exemplary care."
McDevitt’s research reveals a troubling trend: when independent clinics are acquired by these giants, transplant referrals drop by 10%, patient survival rates fall by 2%, hospitalizations increase by 5%, and infection rates rise by 12%. These findings have sparked intense debate, with the companies disputing such criticisms. Fresenius emphasizes its commitment to improving quality of life and clinical outcomes, while DaVita touts its "high-quality, individualized care."
But this is the part most people miss: since 2013, health surveyors have cited U.S. dialysis centers for over 115,000 deficiencies, including poor hygiene, unsanitary conditions, and inadequate training. While Fresenius notes that 65% of its centers received three stars or higher on Medicare’s rating scale, questions remain about the systemic issues plaguing the industry.
Blumenthal’s letter to FTC Chairman Andrew Ferguson underscores the urgency of the situation, labeling the industry as "ripe with predatory, monopolistic potential practices." He argues that the anti-competitive environment demands a thorough investigation. Fresenius has confirmed its cooperation with the FTC, but the agency and DaVita have yet to comment.
Is this a case of corporate greed overshadowing patient care? Or are Fresenius and DaVita unfairly maligned for providing a vital service? The debate is far from over, and Blumenthal’s call for transparency could be a turning point. What do you think? Are these companies abusing their market power, or are they being unjustly targeted? Let us know in the comments below.
